BCM
NERV icon

Bridgeway Capital Management’s Minerva Neurosciences NERV Stock Holding History

Bridgeway Capital Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,436
Closed -$24.5K – 1413
2022
Q4 		$24.5K Sell
15,436
-712
-4% -$3.08K ﹤0.01% 1330
2022
Q3 		$149K Hold
16,148
– – ﹤0.01% 1201
2022
Q2 		$53K Sell
16,148
-2
-0% -$8 ﹤0.01% 1278
2022
Q1 		$107K Sell
16,150
-6,214
-28% -$38.1K ﹤0.01% 1253
2021
Q4 		$143K Sell
22,364
-1,286
-5% -$12.1K ﹤0.01% 1192
2021
Q3 		$329K Buy
23,650
+12,500
+112% +$188K 0.01% 1135
2021
Q2 		$207K Sell
11,150
-18,067
-62% -$389K ﹤0.01% 1256
2021
Q1 		$683K Sell
29,217
-688
-2% -$17.2K 0.01% 1006
2020
Q4 		$560K Buy
29,905
+11,125
+59% +$280K 0.01% 904
2020
Q3 		$478K Buy
+18,780
New +$508K 0.01% 905
2020
Q1 		– Sell
-9,338
Closed -$531K – 1335
2019
Q4 		$531K Hold
9,338
– – 0.01% 957
2019
Q3 		$579K Buy
9,338
+25
+0.3% +$1.42K 0.01% 888
2019
Q2 		$419K Hold
9,313
– – 0.01% 1025
2019
Q1 		$586K Hold
9,313
– – 0.01% 980
2018
Q4 		$502K Sell
9,313
-2,587
-22% -$189K 0.01% 1003
2018
Q3 		$1.2M Sell
11,900
-6,250
-34% -$470K 0.01% 809
2018
Q2 		$1.2M Hold
18,150
– – 0.01% 809
2018
Q1 		$908K Buy
18,150
+525
+3% +$25.2K 0.01% 886
2017
Q4 		$853K Hold
17,625
– – 0.01% 899
2017
Q3 		$1.07M Hold
17,625
– – 0.01% 825
2017
Q2 		$1.25M Buy
17,625
+7,625
+76% +$494K 0.02% 743
2017
Q1 		$648K Hold
10,000
– – 0.01% 972
2016
Q4 		$940K Sell
10,000
-6,512
-39% -$665K 0.01% 848
2016
Q3 		$1.86M Sell
16,512
-4,825
-23% -$468K 0.03% 557
2016
Q2 		$1.74M Buy
21,337
+9,950
+87% +$633K 0.03% 575
2016
Q1 		$559K Buy
11,387
+2,500
+28% +$107K 0.01% 995
2015
Q4 		$432K Buy
8,887
+4,119
+86% +$172K 0.01% 1106
2015
Q3 		$200K Buy
4,768
+2,268
+91% +$104K ﹤0.01% 1309
2015
Q2 		$116K Buy
+2,500
New +$107K ﹤0.01% 1417

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Bridgeway Capital Management's NERV Position: Q1 2023 in Review

Bridgeway Capital Management sold out of Minerva Neurosciences (NERV) in Q1 2023, closing a stake of 15,436 shares — an estimated $24.5K sold.

Bridgeway Capital Management first reported a position in NERV in Q2 2015 and held it in 29 quarters. The position peaked at $1.86M in Q3 2016. 17 funds tracked by Wall St. Rank hold NERV as of Q1 2023.

  • Bridgeway Capital Management reported no remaining Minerva Neurosciences position as of Q1 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 15,436 Minerva Neurosciences shares in Q1 2023, an estimated $24.5K.
  • Bridgeway Capital Management first reported a position in Minerva Neurosciences in Q2 2015 and held it in 29 quarters.
  • Bridgeway Capital Management's Minerva Neurosciences position peaked at $1.86M in Q3 2016.
  • 17 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2023.

Based on Bridgeway Capital Management's 13F filing for Q1 2023, filed 15 May 2023.